Lexaria Bioscience (LEXX) EBITDA Margin (QoQ) (2018 - 2025)
Lexaria Bioscience (LEXX) EBITDA Margin (QoQ) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | 61,024.00 |
| May 31, 2025 | -57,437.00 |
| Feb 28, 2025 | -11,809.00 |
| Nov 30, 2024 | 115,974.00 |
| Aug 31, 2024 | -54,779.00 |
| May 31, 2024 | -161,421.00 |
| Feb 29, 2024 | 29,232.00 |
| Nov 30, 2023 | 287,118.00 |
| Aug 31, 2023 | -53,455.00 |
| May 31, 2023 | 352,022.00 |
| Feb 28, 2023 | -487,515.00 |
| Nov 30, 2022 | -106,125.00 |
| Aug 31, 2022 | 175,174.00 |
| May 31, 2022 | 230,130.00 |
| Feb 28, 2022 | 970,781.00 |
| Nov 30, 2021 | -1.02 Mn |
| Aug 31, 2021 | -294,153.00 |
| May 31, 2021 | -68,252.00 |
| Feb 28, 2021 | -62,231.00 |
| Nov 30, 2020 | 139,536.00 |